IMUX
Immunic IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$155.25M
P/E Ratio
—
EPS
$-0.63
Beta
1.37
52W High
$1.51
52W Low
$0.51
50-Day MA
$0.98
200-Day MA
$0.84
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunic Inc
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-103.06M |
| Operating Margin | 0.00% |
| Return on Equity | -1653.00% |
| Return on Assets | -198.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.06 |
| Price-to-Book | 12.72 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $130.47M |
| Float | $121.08M |
| % Insiders | 1.02% |
| % Institutions | 55.29% |
Analyst Ratings
Consensus ($5.25 target)
9
BuyData last updated: 4/8/2026